# CKD Mineral and Bone Disease

## Overview

CKD mineral and bone disorder (CKD-MBD) is a systemic disorder of mineral metabolism unique to kidney disease. It encompasses dysregulation of phosphate, calcium, fibroblast growth factor-23 (FGF-23), parathyroid hormone (PTH), and vitamin D, resulting in abnormalities of bone architecture (renal osteodystrophy), vascular calcification, and systemic mineral imbalance. CKD-MBD significantly contributes to cardiovascular mortality and morbidity in CKD and ESRD populations.

High-Yield Board Point

CKD-MBD reflects interacting phosphate handling, vitamin D, calcium and parathyroid changes. Interpret serial calcium, phosphate and PTH together. The approximate PTH range of 2–9 times the assay upper normal limit applies to **CKD G5D**. In nondialysis CKD G3a–G5, an optimal PTH target is unknown; investigate a progressively rising or persistently elevated value for modifiable causes. [KDIGO 2017 recommendations 4.2.1 and 4.2.3](https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf).

## Pathophysiology: The Cascade

### Phase 1: Early CKD (G3a–G3b, eGFR 30–59)

#### Phosphate Retention

- eGFR decline → reduced filtered phosphate load → serum phosphate rises (mild, ~3.5–4.5)
- Phosphate rise stimulates **FGF-23 production** (by osteocytes)

#### FGF-23 Elevation

- FGF-23 acts via **FGF receptor + Klotho** (Klotho is a co-factor; highly expressed in kidney and parathyroid)
- FGF-23 increases phosphate excretion (tubular)
- FGF-23 **suppresses 1,25-dihydroxyvitamin D \[1,25(OH)₂D\]** production (downregulates 1-alpha hydroxylase)
- FGF-23 **directly suppresses PTH secretion** (early phase)

#### Vitamin D Decline

- Reduced 1,25(OH)₂D production → reduced calcium reabsorption in intestine
- Hypocalcemia develops (mild, often \<8.5 mg/dL)

### Phase 2: Progressive CKD (G4, eGFR 15–29)

#### Phosphate Accumulation

- Serum phosphate rises further (\>4.5 mg/dL)
- Hyperphosphatemia directly stimulates PTH secretion

#### Secondary Hyperparathyroidism (SHPT) Develops

- Hypocalcemia + hyperphosphatemia + low 1,25(OH)₂D → PTH secretion rises
- Parathyroid gland hyperplasia develops (chronic stimulation)
- PTH rises disproportionately; negative feedback loop broken

#### PTH Effects

- Increased bone resorption (osteoclast activation)
- Increased 1,25(OH)₂D production (via 1-alpha hydroxylase in residual renal tubules)
- Increased phosphate excretion (but diminishing effect with declining GFR)

### Phase 3: ESRD (G5, eGFR \<15)

#### Severe Dysregulation

- Serum phosphate \>5.0 mg/dL (often 6–8)
- PTH severely elevated (often \>500–1000 pg/mL if untreated)
- Calcium may be normal or elevated (from PTH-driven mobilization + loss of Klotho signaling)
- FGF-23 extreme elevation (\>1000 pg/mL)

#### Consequences

- **Bone:** Severe renal osteodystrophy; pathologic fractures
- **Vascular:** Extensive calcification of coronary arteries, arterial walls, soft tissues
- **Systemic:** Hyperkalemia, metabolic acidosis, anemia (from EPO resistance + PTH suppression), cardiac arrhythmias

## Types of Renal Osteodystrophy (ROD)

Bone biopsy classifies renal osteodystrophy when histology will change management. PTH and bone-specific alkaline phosphatase can support turnover assessment, but do not reliably classify every individual.

### High Bone Turnover Disease (Osteitis Fibrosa)

|  |  |
|----|----|
| **Pathology** | Increased osteoblast and osteoclast activity; peritrabecular fibrosis |
| **Biomarkers** | PTH \>300 pg/mL (typically), high alkaline phosphatase, elevated P1NP |
| **Prevalence** | ~70–80% of ESRD patients on dialysis |
| **Pathophysiology** | SHPT → excessive PTH → bone resorption outpaces formation |
| **Clinical Features** | Bone pain, proximal weakness, high fracture risk despite high turnover (paradox: increased turnover but poor bone quality) |
| **Management** | Target phosphate, normalize calcium, PTH suppression with vitamin D ± calcimimetics |

### Adynamic Bone Disease

|  |  |
|----|----|
| **Pathology** | Low bone turnover with reduced osteoblast and osteoclast activity; low bone formation |
| **Biomarkers** | PTH \<150 pg/mL (classically), low-normal alkaline phosphatase, low P1NP |
| **Prevalence** | ~20–30% of ESRD; increasing due to aggressive PTH suppression |
| **Pathophysiology** | Excessive suppression of PTH (over-treatment with vitamin D/calcimimetics); accumulation of aluminum or strontium |
| **Risk Factors** | Chronic aluminum exposure (contaminated dialysate, binders), over-aggressive PTH suppression, older age, diabetes |
| **Clinical Features** | Fracture risk paradoxically high (poor bone formation despite low resorption); slow healing |
| **Management** | Avoid further PTH oversuppression; review calcium loading, active vitamin D and calcimimetics; evaluate suspected aluminum exposure. Individualize treatment for low-turnover bone disease. |

### Osteomalacia

|  |  |
|----|----|
| **Pathology** | Defective mineralization; accumulation of unmineralized osteoid |
| **Biomarkers** | Low PTH, elevated alkaline phosphatase, elevated osteoid volume on biopsy |
| **Pathophysiology** | Severe vitamin D deficiency (decreased 1,25(OH)₂D); aluminum deposition in bone |
| **Clinical Features** | Bone pain, muscle weakness, fractures |
| **Management** | Vitamin D (native or active form); treat aluminum exposure |

### Mixed Uremic Osteodystrophy

|  |  |
|----|----|
| **Pathology** | Features of both high turnover and low turnover disease; heterogeneous bone changes |
| **Biomarkers** | Intermediate PTH, variable alkaline phosphatase |
| **Prevalence** | ~5–10% of ESRD |
| **Management** | Balance PTH suppression; optimize phosphate and calcium; vitamin D supplementation |

Clinical Pearl

The classic teaching—“high PTH = high turnover, low PTH = low turnover”—is helpful but incomplete. PTH oversuppression, calcium loading, diabetes, aging, and some toxic exposures can contribute to low turnover. Vitamin D deficiency raises a separate concern for impaired mineralization; withholding vitamin D is not an established cause of adynamic disease. Interpret biomarker trends and consider bone biopsy when the result would change treatment.

## Vascular Calcification in CKD-MBD

### Pathophysiology

Hyperphosphatemia and elevation of the calcium-phosphate product (Ca × P) drive vascular smooth muscle cell phenotypic transition to osteogenic cells, resulting in calcification. Unlike atherosclerotic calcification (intimal), uremic calcification is predominantly **medial** (vascular wall) and is mediated by loss of natural inhibitors (fetuin-A, pyrophosphate).

### Clinical Consequences

- **Arterial stiffness** → increased pulse pressure → LVH → diastolic dysfunction
- **Coronary artery calcification** → accelerated CAD; increased MI risk
- **Medial sclerosis** → reduced arterial compliance; poor coronary perfusion
- **Valvular calcification** → aortic/mitral disease
- **Soft tissue calcification** → calciphylaxis (rare but life-threatening); metastatic calcification

### Mortality Impact

Coronary artery calcification score independently predicts cardiovascular death in CKD and ESRD populations.

## KDIGO 2017 CKD-MBD Targets by Stage

| Stage | eGFR | PTH | Phosphate | Calcium | Notes |
|----|----|----|----|----|----|
| **G3a** | 45–59 | No established target; assess trend and modifiable causes | Treat persistent/progressive elevation toward normal | Avoid hypercalcemia | Review calcium, phosphate, and PTH together |
| **G3b** | 30–44 | No established target; assess trend and modifiable causes | Treat persistent/progressive elevation toward normal | Avoid hypercalcemia | Preserve nutrition; do not start preventive binders for normal phosphate |
| **G4** | 15–29 | No established target; assess trend and modifiable causes | Treat persistent/progressive elevation toward normal | Avoid hypercalcemia | Correct vitamin D deficiency; reserve active vitamin D for severe progressive hyperparathyroidism |
| **G5D** | Dialysis-dependent | Approximately 2–9 times assay upper normal limit | Lower elevated phosphate toward normal | Avoid hypercalcemia | Individualize PTH treatment using trends, calcium, phosphate, and turnover risk |

Key Point

Avoid rapid, aggressive changes in mineral parameters. Overcorrection (excessive PTH suppression, hypercalcemia) risks adynamic bone disease and calcification. Lower persistently elevated phosphate toward normal, avoid hypercalcemia, and assess PTH using the dialysis-specific framework or nondialysis trend assessment as appropriate.

## Management Strategy

### Phosphate Management

#### Dietary Restriction

- Target: \<1000–1200 mg/day (vs. normal 1000–1500 mg/day)
- Education: Limit dairy, processed meats, nuts, whole grains
- Challenge: Palatability and adherence in advanced CKD

#### Phosphate Binders

Used when dietary restriction alone is inadequate (typically when serum P \>4.5 mg/dL in G4–G5).

| Binder Class | Agent | Mechanism | Advantages | Disadvantages |
|----|----|----|----|----|
| **Calcium-based** | Calcium carbonate, calcium acetate | Binds PO₄ in gut; increases Ca absorption | Inexpensive; improves Ca balance | Risk of hypercalcemia; promotes vascular calcification if used excessively |
| **Non-calcium** | Sevelamer HCl, sevelamer carbonate | Polymer binds phosphate | No hypercalcemia risk; may lower cholesterol | GI side effects; large pill burden |
| **Lanthanum carbonate** | Lanthanum | Rare earth binds phosphate | Effective; reasonable pill burden | Minimal long-term safety data; rare GI toxicity |
| **Iron-based** | Sucroferric oxyhydroxide, ferric citrate | Iron core binds phosphate | Effective; may improve iron status (ferric citrate) | GI upset possible; dark stool |
| **Magnesium-based** | Magnesium carbonate | Magnesium + carbonate binds phosphate | Avoids Ca/Al excess | Hypermagnesemia risk (usually offset by dialysis) |

KDIGO 2017 Recommendation

“Restrict dose of calcium-based binders; calcium-free binders may favor halting progression of vascular calcification compared with calcium-containing binders.”

Practical Approach

- **G3b–G4:** Start dietary restriction; add binder only if persistent hyperphosphatemia
- **G5D:** Use combination therapy (non-calcium binder + smaller dose calcium binder, or non-calcium monotherapy)

### Vitamin D Supplementation

| Type | Agent | Indication | Advantages | Disadvantages |
|----|----|----|----|----|
| **Native** | Cholecalciferol (D3) | CKD G3–G4 with low 25(OH)D | Safe; physiologic; inexpensive | Slow onset; may not be adequate in G4 with very low 1,25(OH)₂D |
| **Active** | Calcitriol, paricalcitol, doxercalciferol | CKD G4–G5D with SHPT | Rapid PTH suppression; improves Ca/P balance | Risk of hypercalcemia; need monitoring; expensive |
| **Calcimimetic** | Cinacalcet, etelcalcetide | SHPT refractory to vitamin D | Suppress PTH directly; no hypercalcemia risk; may reduce need for parathyroidectomy | Nausea, vomiting; risk of hypocalcemia; expensive |

KDIGO Recommendations

- **CKD G3a–G5D with vitamin D deficiency or insufficiency:** Correct using strategies recommended for the general population; KDIGO does not set a universal 25(OH)D threshold of 30 ng/mL.
- **CKD G5D requiring PTH-lowering therapy:** Choose a calcimimetic, calcitriol/vitamin D analog, or combination using serial PTH, calcium, phosphate, and turnover risk. A PTH above 150 pg/mL alone is not an indication; avoid treatment-driven oversuppression.
- **Calcium:** Avoid hypercalcemia in adults. Interpret calcium with serial phosphate and PTH and the local assay; KDIGO does not prescribe a universal serum calcium target of 8.5–10.0 mg/dL.

### Parathyroidectomy Indications

When to Refer to Surgery

- **SHPT refractory to medical management:** PTH \>800 pg/mL, hypercalcemia (despite binders, vitamin D, calcimimetics), symptomatic (bone pain, fractures)
- **Non-adherence to dialysis/therapy:** Patient unable/unwilling to take medications
- **Duration:** Usually after 6–12 months of failed medical management
- **Post-transplant:** Tertiary SHPT with persistent hypercalcemia + hyperparathyroidism
- **Surgical approaches:** Subtotal parathyroidectomy or total with autotransplant

Post-Operative Warning: Hungry Bone Syndrome

Post-parathyroidectomy, monitor Cr, calcium, phosphate. Administer IV calcium + dextrose to prevent “hungry bone syndrome” (acute hypocalcemia from rapid bone healing).

## Bone Biopsy and Biomarkers

### When to Biopsy

Not routinely recommended; consider if:

- Unexplained fractures or bone pain despite normal biochemistry
- Severe hypercalcemia with suppressed PTH (suspect adynamic bone disease or aluminum)
- Before parathyroidectomy decision (to assess bone turnover)

### Non-Invasive Biomarkers

| Marker | Interpretation | Use |
|----|----|----|
| **PTH (intact)** | High → high turnover; low → low turnover | Primary screening; KDIGO targets |
| **Alkaline phosphatase (ALP)** | Elevated with high turnover; normal/low with low turnover | Adjunctive; supports PTH findings |
| **Bone-specific ALP** | More specific for bone than total ALP | Less used; when available, specific for bone turnover |
| **P1NP** | Marker of bone formation; high in high turnover | Research; emerging use in clinical practice |
| **CTX** | Marker of bone resorption | Less used in CKD; more in osteoporosis research |
| **FGF-23** | Markedly elevated in CKD; reflects phosphate burden | Research marker; not routinely ordered; prognostic for CV events |

Clinical Pearl

Trends matter more than absolute values. A PTH rising from 100 to 400 pg/mL over months indicates worsening SHPT and need for intervention, even if \<500. Conversely, stable PTH at 200 in a patient with good phosphate control may not need adjustment.

## FGF-23 and Future Therapies

### Pathophysiologic Role

FGF-23 is markedly elevated in CKD and associated with:

- Increased cardiovascular mortality (independent of PTH, phosphate, Klotho)
- LVH and cardiac dysfunction
- Anemia (FGF-23 suppresses erythropoietin)
- Bone disease

**Mechanism:** Loss of Klotho (kidney is primary source) → reduced FGF-23 signaling → unchecked phosphate retention and PTH activation.

### Emerging Therapies

#### FGF-23 Antagonists and Klotho Analogs

- In development for CKD and ESRD
- Aim to restore Klotho signaling and suppress FGF-23
- Early trials show promise in reducing phosphate and PTH without hypercalcemia
- Not yet standard clinical practice

## References

1.  KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD. *Kidney Int Suppl*. 2017;7(1):1-59. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30675420/)
2.  Executive Summary of the 2017 KDIGO CKD-MBD Guideline Update. *Kidney Int*. 2017;92(1):26–36. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28646995/)

## Related Mastery Modules

### Also on this topic

The same subject at other levels of depth.

- **Interactive case:** [CKD-Mineral and Bone Disorder](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/mercy/case5_ckd_mbd.html)
- **Student handout:** [CKD Mineral-Bone Disorder (CKD-MBD): Pathophysiology \&amp; Management](https://urinenephrology.org/student-resources/ckd/ckd-mbd-student-handout.html)


---

[Website version](https://urinenephrology.org/mastery/ckd-advanced/ckd-mbd.html) · Markdown synchronized October 3, 2026.